Abcam (OTCMKTS:ABCZF) versus Cybin (OTCMKTS:CYBN) Head to Head Analysis

Cybin (OTCMKTS:CYBN) and Abcam (OTCMKTS:ABCZF) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares Cybin and Abcam’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-93.17%	-84.68%
Abcam	N/A	N/A	N/A

Valuation and Earnings

This table compares Cybin and Abcam”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$35.93 million	($3.89)	-2.13
Abcam	N/A	N/A	N/A	C$0.17	130.73

Cybin is trading at a lower price-to-earnings ratio than Abcam, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

17.9% of Cybin shares are held by institutional investors. Comparatively, 43.6% of Abcam shares are held by institutional investors. 15.0% of Cybin shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for Cybin and Abcam, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0	0	3	0	3.00
Abcam	0	0	0	0	0.00

Cybin currently has a consensus target price of $50.00, suggesting a potential upside of 503.86%. Given Cybin’s stronger consensus rating and higher possible upside, analysts clearly believe Cybin is more favorable than Abcam.

Summary

Abcam beats Cybin on 5 of the 9 factors compared between the two stocks.

About Cybin

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.

About Abcam

Abcam Limited, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company’s principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. Abcam Limited was formerly known as Abcam plc and changed its name to Abcam Limited in December 2023. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom. As of December 6, 2023, Abcam Limited operates as a subsidiary of Danaher Corporation.